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Two B7 molecules have been identified: B7.1 (CD80)*Department of Molecular and Cellular Biology
(Freeman et al., 1989, 1991) and B7.2 (CD86) (Azuma etUniversity of California at Berkeley
al., 1993a; Freeman et al., 1993a, 1993b; Chen et al.,Berkeley, California, 94720
1994). Transfection studies have demonstrated that²Howard Hughes Medical Institute
both B7.1 and B7.2 can serve as ligands for costimula-and Department of Microbiology and Immunology
tion in vitro (Linsley et al., 1991b; Gimmi et al., 1991;Beckman Center
Freeman et al., 1991, 1993b; Chen et al., 1994). However,Stanford University
it is not known whether these molecules mediate distinctStanford, California, 94305
or overlapping functions in vivo. Anti-B7.1 monoclonal
antibodies (MAbs) have only minimal effect on primary
mixed lymphocyte reactions or T cell proliferation to
Summary Mlsa stimulation (Azuma et al., 1993a; Lenschow et al.,
1993; Hathcock et al., 1994), and immune responses are
Transgenic mice were generated to explore theeffects only partially impaired in mice in which the B7.1 gene
on lymphoid development and immune function of is inactivated by homologous recombination (Sharpe,
constitutive expression of murine B7.2 on B and T 1995). In vivo, anti-B7.2 MAb was shown to be more
cells. The number of B lymphocytes in primary and efficient than anti-B7.1 MAbat blocking theexpansion of
secondary lymphoid tissues is normal in B7.2 trans- Ag-specific T cells (Kearney et al., 1995) and prolonging
genic lines expressing low levels of B7.2 on B cells, allogenic islet graft survival (Lenschow et al., 1995a).
but markedly reduced in transgenic lines expressing B7.2 is expressed at much higher levels than B7.1 on
moderate to high levels of the transgene on B cells. professional antigen-presenting cells (APC) such as
This reduction is not due to an intrinsic abnormality dendritic cells, macrophages, and activated B cells
of the transgenic B cells, but is rather theconsequence (Lenschow et al., 1993, 1994; Caux et al., 1994; Hathcock
of an elimination by an immune mechanism requiring et al., 1994; Inaba et al., 1994; Stack et al., 1994; Con-
the engagement of CD28 on T cells. Interestingly, dur- stant et al., 1995). Based on these observations, it has
ing cognate antigen-specific interaction with T cells been proposed that B7.2 is the primary costimulatory
in vivo, B7.2 transgenic B cells are not eliminated, molecule for the initiation of T cell immune responses.
but proliferate and differentiate normally. Our findings Recent studies have suggested that B7 molecules
do not always provide positive costimulatory signals insuggest that, in the absence of high affinity ligand for
vivo for T cell±dependent immune responses. Trans-the TCR, the CD28±B7.2 system participates in the
genic mice constitutively expressing B7.1 on B lympho-regulation of B cell homeostasis.
cytes are deficient in T-dependent antibody production
(Sethna et al., 1994). Moreover, treatment of nonobese
diabetic (NOD) mice with anti-B7.1 MAb has been re-
Introduction ported to accelerate the disease course (Lenschow et
al., 1995b). It has been suggested that these effects may
T lymphocytes require two signals for optimal prolifera- reflect the preferential engagement of CTLA-4 by B7.1.
tion and inductionof effector functions (Schwartz, 1990). Nevertheless, it has been shown that B7.1 becomes the
Signal one is delivered by the engagement of the T cell functionally dominant costimulatory molecule involved
antigen receptor (TCR) with the peptide±major histo- in epitope spreading and clinical relapses of murine EAE
compatibility complex (MHC) complex. The second sig- (Miller et al., 1995). Moreover, B7.1 transgenic models of
nal is antigen independent and provided by the ligation autoimmunity (Harlan et al., 1994; Guerder et al., 1994a,
of accessory molecules. Activation of the TCR in the 1994b) and studies demonstrating enhanced immuno-
absence of costimulatory signals results in T cell unre- genicity of B7.1-transfected tumors (Chen et al., 1992;
sponsiveness or anergy (Mueller et al., 1989). The occur- Townsend and Allison,1993; Baskar et al., 1993) indicate
rence of costimulation in the absence of TCR stimulation that B7.1 has a positive costimulatory function in vivo.
is considered to be a neutral event. Experiments using antibodies to block B7.1 or B7.2 dur-
It is now accepted that the cell surface molecule CD28 ing immune responses in vivo have yielded mixed re-
is the major costimulatory receptor for T cells (reviewed sults. While anti-B7.1 MAb treatment reduced the inci-
by Linsley and Ledbetter, 1993; June et al., 1994; Allison, dence of disease of murine EAE, anti-B7.2 MAb made
1994). CD28 is highly homologous to CTLA-4, an induc- the disease worse (Kuchroo et al., 1995). It has been
ible protein expressed on T cells (Brunet et al., 1987; suggested that this differential effect of the B7 MAbs
Harper et al., 1991). In contrast with CD28, CTLA-4 ap- reflected the ability of B7.1 and B7.2 to direct T cell
pears to be a negative regulator of T cell activation differentiation along the T helper type 1 (Th1) or Th2
(reviewed by Chambers et al., 1996). Although these two pathway, respectively. However, anti-B7.2 MAb treat-
receptors have opposing functions, they share common ment blocked the development of diabetes inNOD mice,
ligands, the members of the B7 family (Linsley et al., a Th1-dependent autoimmune disease (Lenschow et al.,
1995b). The observation that interruption of B7.1- or1990, 1991a, 1991b; Azuma et al., 1993a; Lenschow et
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B7.2-mediated interactions can have opposite out- 31, and 33). Heterozygous transgenic mice from all lines
were healthyand maintained in a pathogen-free environ-comes in different models of T cell±mediated autoim-
mune diseases emphasizes that the interplay between ment according to theAnimal Care guidelines (University
of California).the B7 molecules and their receptors is highly complex.
An additional level of complexity in the B7/CD28/
CTLA-4 system is that the expression of the B7 mole-
cules is not exclusively restricted to ªconventionalº APC. B7-2 Transgenic Mice Express the Transgene
on B, T, and NK1.11 CellsFor example, B7.2 is found on unstimulated T cells and
B7.1 is expressed after activation (Azuma et al., 1993b; Cell suspensions from lymphoid tissues were stained
with an anti-B7.2 MAb (GL-1) in combination with anti-Hathcock et al., 1994; Prabhu Das et al., 1995; Krummel
and Allison, 1995). These molecules appear to be recip- bodies directed against various cell surface markers
and analyzed by flow cytometry to determine transgenerocally regulated on the surface of T cell clones (Prabhu
Das et al., 1995), but the physiological significance of T expression in the cell populations. As previously re-
ported (Hathcock et al., 1994; Prabhu Das et al., 1995;cell expression of B7 molecules has yet to be estab-
lished. Krummel and Allison, 1995), B7.2 was expressed mini-
mally on B lymphocytes and at more significant levels onTo gain a better understanding of the influence and
importance of B7.2 on immune responses in vivo, we T cells in nontransgenic animals (Figure 1A). Increased
levels of B7.2 were found only on 20%±50% of the Thave generated transgenic mice that constitutively ex-
press this molecule in lymphocytes. The transgene we cells in the transgenic line 16. No expression of the
transgene was observed in lines 23 and 33. The otherused contains a MHC class I promoter and the immuno-
globulin m (Igm) enhancer to allow expression in T and B transgenic lines showed increased expression of B7.2
on both B and T cells. These lines could be divided intocells. Analysis of three different transgenic lines reveals
that constitutive expression of B7.2 at moderate to high three groups based on the intensity of B7.2 expression
on B cells: low (lines 26 and 31), moderate (line 27), andlevels on B lymphocytes leads to their elimination by a
T cell±mediated mechanism. Our experiments indicate moderate to high (line 7) (Figure 1B). In all lines, T cells
expressed very high levels of B7.2 (Figure 1B). Low lev-that the elimination of the B7.2 transgenic B cells does
not occur when they present a high affinity ligand for els of B7.2 were also detected on NK1.11 cells (data
not shown). The levels of B7-2 on macrophages andthe TCR. Together, these results suggest that the B7.2/
CD28 system may play a dual role in the regulation of dendritic cells were identical to those of nontransgenic
littermates, and B7.2 expression was not detectable onB cell homeostasis.
granulocytes (data not shown). The magnitude of the
B7.2 cell surface expression on peripheral B cells inResults
lines 26, 31, and 27 was lower than that of in vitro acti-
vated wild-type B cells (Figure 1C). In line 7, the majorityGeneration of Transgenic Mice Overexpressing B7-2
To generate transgenic mice overexpressing the mouse of B cells expressed B7.2 levels that were comparable
with those of anti-m activated wild-type B cells.B7-2 protein in lymphoid cells, a construct containing
the coding region of the B7-2 cDNA, the H-2Kb promoter, In this report we describe the analysis of the heterozy-
gous offspring from the transgenic lines expressing lowand the immunoglobulin heavy chain enhancer (Pircher
et al., 1989) was injected into oocytes. Eight founder (line 31), moderate (lines 27), and high levels (line 7) of
B7-2 on B lymphocytes. These lines will subsequentlymice were obtained carrying 5±80 copies of the trans-
gene. Seven founders were crossed successfully to be referred as B7.2low (line 31), B7.2mod (line 27), and B7.2hi
(line 7).C57Bl/6 mice to establish lines (lines 7, 16, 23, 26, 27,
Figure 1. B7.2 Expression on B and T Cells
in Wild-Type and Transgenic Mice
Splenocytes from wild-type (A) and B7.2
transgenic mice (B) were stained with MAbs
specific for B7.2 (thick lines) and B220 or Thy-
1.2 or with an isotype-matched irrelevant
MAb (thin lines). Data were electronically
gated for B2202 (left panel) or Thy-1.21 (right
panel) cells. Shown in (C) is B7.2 expression
on wild-type B cells stimulated with LPS
(thick line)or anti-IgM MAb (broken line). Con-
trol staining was carried out with an isotype-
matched irrelevant MAb (thin line). Data pre-
sented are gated on B2201 cells.
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Table 1. B and T Cell Populations in Lymphoid Tissues of B7.2low and B7.2mod Transgenic Mice
Spleen Lymph Nodes Bone Marrow
CD41a CD81a CD41a CD81a Blood B2201 B2201
B2201 CD41 CD81 CD44hi CD44hi B2201 CD41 CD81 CD44hi CD44hi B2201 IgM2 IgM1
Mice (3 1026) (3 1026) (3 1026) (%) (%) (3 1026) (3 1026) (3 1026) (%) (%) (%) (%) (%)
B7.2low
Wild type 75 6 22 24 6 7 12 6 2 20 6 2 25 6 6 7.6 6 2.5 7.9 6 2.4 4.6 6 1.5 8 6 1 18 6 3 45 6 6 32 6 7 26 6 6
Transgenic 69 6 9 27 6 11 44 6 28 39 6 3 74 6 4 9.0 6 2.8 6.6 6 3.3 4.6 6 1.7 12 6 3 31 6 3 41 6 6 26 6 9 20 6 7
B7.2mod
Wild type 74 6 14 18 6 5 10 6 4 23 6 4 30 6 14 6.2 6 1.7 7.5 6 1.7 4.3 6 1.4 11 6 3 16 6 5 45 6 5 35 6 5 22 6 7
Transgenic 11 6 7 13 6 6 11 6 10 46 6 16 56 6 4 0.8 6 0.6 9.0 6 2.0 5.0 6 2.0 19 6 4 32 6 1 10 6 1 5 6 2 2 6 1
Values represent the arithmetic mean 6 standard deviation obtained from the analysis of four transgenic mice and four wild-type littermates.
Mice were 4±5 weeks old.
a Values are expressed as the percentage of CD41 or CD81 cells expressing high levels of CD44.
B7.2mod and B7.2hi Transgenic Mice Have effect on thymocyte subset composition, and the thy-
mus housed normal numbers of cells (data not shown).Reduced Numbers of B Cells
However, peripheral T cellsconsistently differed in someB7-2low Transgenic Mice
respects from their normal counterparts (Table 1). TheTransgenic mice expressing low levels of B7.2 on B cells
CD81 T cell population was increased in the spleen but(line 31) had similar numbers of splenic and lymph node
not in the lymph nodes of the transgenic animals. ThisB2201 cells to that found in wild-type littermates. A
augmentation was observed in all transgenic mice ana-normal frequency of B cells was observed in the bone
lyzed, although the magnitude of the increase was vari-marrow (Table 1). No significant differences in the fre-
able. The absolute number of CD41 cells was normal inquency of B cells in blood were found between
the peripheral lymphoid tissues. In both the spleen andtransgenic and control mice (wild-type, 50 6 5%, n 5
lymph nodes of transgenic mice, an increased fraction30; transgenic, 43 6 6%, n 5 40). The phenotype of
of CD81 and CD41 T cells were CD44hi (Table 1). How-the transgenic B cells, as assessed by the light scatter
ever, the level and frequency of expression of early acti-properties and expression of MHC class II, MEL-14 (Fig-
vation markers like CD69 and CD25 were not signifi-ure 2), and other cell surface markers (B220, IgM, CD40,
cantly different (data not shown). B7-2 levels on purifiedCD25, CD44, and HSA), was not significantly different
B7.2low transgenic B cells were insufficient to supportfrom that of wild-type B cells. These results indicate
an allogenic response by CD41 T cells (data not shown),that transgene-induced expression of B7.2 at low levels
suggesting that the increased frequency of T cells withdid not cause significant alterations in B cell maturation.
a partial activated phenotype is not due to the ability ofHigh levels of B7.2 expression on T cells had no major
B cells to provide costimulation. However, in contrast
with wild-type T cells, highly purified B7.2 transgenic T
cells proliferated in response to submitogenic concen-
trations of anti-CD3. This proliferative response was
completely blocked by an anti-B7.2 MAb (Figure 3), indi-
cating that B7.2 transgenic T cells are capable of auto-
crine costimulation via the CD28 activation pathway.
These results suggest that the increased percentage of
CD44hi T cells in B7.2low transgenic mice might result
from the interaction between CD28 and B7.2 expressed
by the T cells. Intriguingly, despite the increased fre-
quency of activated CD81 and CD41 T cells, histological
examination of solid organs revealed no signs of autoim-
munity. Moreover, the transgenic mice showed no alter-
ations in serum immunoglobulin isotypes (Figure 4A).
B7.2mod Transgenic Mice
In contrast with the absence of alterations in the B cell
compartment in the B7.2low mice, transgenic mice ex-
pressing moderate levels of B7.2 on B lymphocytes (line
27) exhibited a dramatic reduction of B cells in all periph-
eral lymphoid tissues (Table 1). This reduction was con-
sistently observed when large numbers of transgenic
mice were compared with their wild-type littermates for
the frequency of B2201 cells in blood (wild-type, 43 6Figure 2. Phenotype of B7.2 Transgenic B Cells
5%, n 5 29; transgenic, 17 6 10%, n 5 26). The few BSplenocytes from wild-type (thin lines) and B7.2low (A), B.72mod (B),
cells found in the periphery had a mature phenotypeand B7.2hi (C) transgenic mice (thick lines) were stained with antibod-
and expressed B220 and surface IgM at levels compara-ies specific for B220 and I-Ab or MEL-14. Data presented are gated
on B2201 splenocytes. ble with wild-type B cells. However, these B cells were
Immunity
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Figure 3. Transgenic T Cells Proliferate in Response to Submito-
genic Amounts of Anti-CD3
We cultured 105 purified wild-type (closed bars) or B7.2low transgenic
(hatched bars) lymph node T cells on 96-well plates previously
coated with 0.1 mg/ml anti-CD3 MAb. Anti-CD28 MAb (1:1000 dilu-
tion of ascites), anti-B7.2 MAb (GL-1; 20 mg/ml), or control rat MAb
(2.4G2; 20 mg/ml) was added in indicated wells. Cultures were incu-
bated for 56 hr, pulsed with 1 mCi of [3H]thymidine, and harvested
after an additional 16 hr.
slightly larger and expressed higher levels of MHC class
II than nontransgenic B cells (Figure 2), suggesting a
state of partial activation. Analysis of the bone marrow
cells revealed that the proportion of pro/pre-B cells
Figure 4. Serum Immunoglobulin Levels in B7.2 Transgenic Mice(B2201IgM2) and immature/mature B cells (B2201IgM1)
was drastically reduced in bone marrow of transgenic Immunoglobulin levels in sera from wild-type littermates and B7.2low
(A) or B7.2hi (B) transgenic mice were measured by ELISA. Eachmice (Table 1), raising the possibility that the peripheral
circle represents an individual mouse.B cell deficiency was due to an impairment in B cell
development.
The T cell composition of primary and secondary effect may be masked in some B7.2hi animals by an
expansion of the peripheral B cell pool as a result of anlymphoid tissues was not altered in B7.2mod transgenic
mice. As in the B7.2low transgenic mice, there was an ongoing immune response. We examined this possibility
by comparing the levels of serum immunoglobulins inincreased frequency of CD81 and CD41 T cells express-
ing high levels of CD44 (Table 1). transgenic and wild-type littermates. Elevated concen-
trations of serum IgG1 were found in some unimmunizedB7.2hi Transgenic Mice
The phenotype of the transgenic mice expressing the B7.2hi transgenic mice, whereas the titers of other iso-
types were not significantly altered (Figure 4B). Thehighest levels of the transgene on B cells (line 7) was
quite variable (Table 2). Some mice had the same pheno- presence of an expanded population of activated B cells
in certain B7.2hi transgenic mice is consistent with thetype as the B7.2mod transgenic line: a sharp reduction in
the absolute numbers of B2201 cells in all peripheral increased size of the transgenic B cells, the higher ex-
pression of MHC class II, and the lower expression oflymphoid tissues (Table 2, transgenic mice 2, 5, 7, and
8). Interestingly, some transgenic mice exhibited a less MEL-14, which was quite dramatic in some animals as
shown in Figure 2. Thus, signs of B cell activation weresevere reduction of B cells in the spleen with an in-
creased absolute number in the lymph nodes (Table 2, apparent in some (but not all) B7.2hi transgenic mice.
However, a reduced number of B cells in the bone mar-transgenic mice 1, 4, and 6). In these transgenic mice
the frequency of B2201 cells in blood was either normal row was found in all transgenic mice examined, sug-
gesting that B cell maturation in B7.2hi transgenic mice,or slightly increased. However, all transgenic mice, re-
gardless of the absolute numberof B cells in their periph- as in B7.2mod mice, may be highly perturbed.
eral lymphoid tissues, exhibited a very low frequency of
B2201 cells in the bone marrow. One possible explana- T Cells Are Responsible for the Paucity
of B Cells in B7.2 Transgenic Micetion for the high variation of the phenotype between
mice and between tissues is that while constitutive ex- The reduced frequency of B cells in the bone marrow
of the B7.2mod and B7.2hi transgenic mice was quite unex-pression of B7.2 has a deleterious effect on B cell devel-
opment as observed in the B7.2mod transgenic line, this pected. This phenotype could be the result of an indirect
Effects of a Constitutive Expression of B7.2 on Lymphocytes
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Table 2. B and T Cell Populations in Lymphoid Tissues of B7.2hi Transgenic Mice
Spleen Lymph Nodes Bone Marrow
CD41a CD81a CD41a CD81a Blood B2201 B2201
Age B2201 CD41 CD81 CD44hi CD44hi B2201 CD41 CD81 CD44hi CD44hi B2201 IgM2 IgM1
Mice (weeks) (3 1026) (3 1026) (3 1026) (%) (%) (3 1026) (3 1026) (3 1026) (%) (%) (%) (%) (%)
WT 4 52 15 8 ND Ð 3.6 4.2 2.5 Ð Ð 40 30 24
TG1 4 45 10 11 Ð Ð 10.1 7.7 5.5 Ð Ð 53 0 13
TG2 4 26 13 9 Ð Ð 1.0 2.9 2.3 Ð Ð 11 7 0
WT 5 70 14 9 Ð Ð 4.3 5.3 3.9 Ð Ð 36 32 20
TG3 5 84 31 11 Ð Ð 7.6 5.2 4.7 Ð Ð 53 6 8
WT 7 105 31 16 19 30 5.3 6.8 4.1 7 17 40 18 14
WT 7 101 27 10 21 25 3.8 6.4 3.4 6 11 53 22 19
TG4 7 68 25 41 32 62 8.9 8.6 7.8 30 48 57 3 3
TG5 7 10 14 13 34 55 1.1 5.3 4.1 23 39 20 20 1
TG6 7 62 27 17 40 70 7.4 5.6 5.0 37 50 74 7 1
WT 9 102 44 27 20 20 4.6 6.5 4.9 17 21 49 25 26
TG7 9 48 54 86 35 60 1.2 6.6 6.2 25 37 13 4 0
TG8 9 76 67 97 50 75 2.6 4.8 5.0 34 53 8 4 1
WT, wild type; TG, transgenic; ND, not determined.
a Values are expressed as the percentage of CD41 or CD81 cells expressing high levels of CD44.
effect onB cell development caused by an inappropriate in the absence of ab T cells. The absolute numbers of
bone marrow B2201IgM2 and B2201IgM1 cells wereinsertion of the transgene into the genome. However,
the effect was observed in multiple founders, making similar in the transgenic and nontransgenic littermates
(Table 3; Figure 5A). These data indicate that the pres-this possibility unlikely. Alternatively, the reduced B cell
numbers may be due to a direct effect caused by the ence of the B7.2 transgene did not perturb B cell differ-
entiation and that T cells are directly responsible for theexpression of the transgene-derived B7.2 itself, or as a
consequence of an immune mechanism mediated by the reduced number of B cells in both B7.2mod and B7.2hi
transgenic mice.B7.2 transgenic T cells. To assess the latter possibility,
transgenic mice were crossed with mice carrying a ge-
nomic deletion in the TCRb locus (TCRb2/2 mice) and T Cell Expression of the B7.2 Transgene Is
Not Necessary for the Elimination of B7.2consequently lacking mature ab T cells (Mombaerts et
al., 1991). Thus, if an intrinsic defect in B cell precursors Transgenic B Cells
Although transgenic T cells proliferated normally whenwas responsible for the effect observed in the transgenic
mice, the perturbations in the Bcell compartment should stimulated with anti-CD3 and anti-CD28 MAbs in vitro
(Figure 3), it was possible that the elimination of thebe reproduced in the absence of T cells. As shown in
Table 3 for the B7.2mod transgenic line and Figure 5A for B7.2 transgenic B cells was the result of a faulty T±B
cell contact or an altered functional status of the T cellsthe B7.2hi transgenic line, we found that TCRb2/2 mice
carrying the B7.2 transgene had the same number of due to their very high levels of B7.2. To determine
whether B7.2 transgenic expression on T cells was nec-splenic and lymph node B cells as their nontransgenic
littermates. No significant differences in cellular size or essary for the elimination of the B7.2 transgenic B cells,
we examined the fate of B7.2 transgenic B cells exposedexpression of MHC class II (Figure 5B) or other cell
surface markers (IgM, B220, CD40, CD44, Fas, LFA-1, in vivo to syngeneic nontransgenic T cells. Syngeneic
wild-type T cells were adoptively transferred into B7.2hiICAM-1, HSA, and MEL-14) were observed on B cells
from the B7.2 transgenic TCRb2/2 mice versus the non- transgenic TCRb2/2 mice and nontransgenic littermates
and the number of B cells in the lymphoid organs wastransgenic B cells. Most importantly, no defect in B
lymphopoiesis was apparent in the transgenic animals determined by flow cytometry 3 weeks after transfer.
Table 3. Recovery of B7.2mod Transgenic B Cells into TCRb2/2, CD282/2, and lpr/lpr Backgrounds
Lymph
Bone MarrowBlood Spleen Nodes
B2201 B2201 B2201 B2201IgM2 B2201IgM1
Mice n (%) (3 1026) (3 1026) (3 1026) (3 1026)
TCRb2/2
TG2 4 76 6 8 65 6 4 9.2 6 0.4 10.9 6 3.8 8.9 6 4.0
TG1 4 76 6 5 66 6 10 11.6 6 3.9 11.5 6 3.0 8.8 6 4.6
CD282/2
TG2 3 43 6 9 83 6 16 19.8 6 2.8 10.4 6 1.4 5.0 6 1.7
TG1 3 38 6 8 77 6 21 18.1 6 2.0 10.2 6 1.2 4.9 6 2.4
lpr/lpr
TG2 3 52 6 5 70 6 22 14.0 6 4.0 12.0 6 3.0 7.0 6 1.0
TG1 4 6 6 6 6 6 5 3.0 6 2.0 2.0 6 1.0 0.0 6 1.0
Values represent the arithmetic mean 6 standard deviation. Mice were 5±6 weeks old. n, the number of mice analyzed. TG, transgenic.
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cell surface markers (CD44, CD45RB, MEL-14, CD25,
and CD69), was equivalent in the B7.2 transgenic and
control mice (data not shown). Identical results were
obtained upon transfer of syngeneic nontransgenic T
cells into nu/nu mice reconstituted previously with B7.2hi
transgenic bone marrow cells (data not shown). Taken
together, these studies demonstrate that the elimination
of the B7.2 transgenic B cells does not require the ex-
pression of the B7.2 transgene on T cells since it also
occurs with normal T cells.
The Elimination of B7.2 Transgenic B Cells Requires
the Expression of CD28 by T Cells
To determine whether the T cell±mediated elimination
of B cells constitutively expressing B7.2 required the
engagement of CD28, the B7.2mod transgenic line was
crossed with mutant mice deficient for the CD28 gene
(Lucas et al., 1995). In contrast with the consistent, dras-
tic B cell deficiency observed in the intact transgenic
animals (Table 1), in the absence of expression of CD28
mice expressing the B7.2 transgene had normal num-
bers of peripheral B lymphocytes (Table 3). Moreover,
the expression of various cell surface antigens (B220,
IgM, I-Ab, CD40, CD25, CD44, LFA-1, ICAM-1, MEL-14,
and HSA) on B7.2 transgenic B cells was similar to that
found on nontransgenic B cells (data not shown). The
frequency of B cells in the bone marrow of the B7.2
Figure 5. B7.2 Transgenic B Cells Are Eliminated In Vivo in the Pres- transgenic CD282/2 mice was also normal (Table 3).This,
ence of Syngeneic Wild-Type T Cells together with the observation that B cell development
Nontransgenic (TG minus) or B7.2 transgenic (TG plus) C57Bl/6 was normal in B7.2 transgenic TCRb2/2 mice, indicates
TCRb2/2 littermates were either untreated (minus) or injected (plus) that B cells constitutively expressing B7.2 are not im-
with 20 3 106 lymph nodes T cells from wild-type C57Bl/6 mice.
paired in their development. In addition, these resultsMice were sacrificed 3 weeks after transfer. Cells from spleen, lymph
show that the elimination of the B7.2 transgenic B cellsnodes (axillary, brachial, and inguinal), and bone marrow were
is dependent on CD28±B7.2 interactions.counted, stained with anti-B220, and analyzed by flow cytometry
to measure the B cells recovery (A). Spleen cells from untreated (B)
or T cell±reconstituted mice (C) were also stained with anti-B220
and anti-I-Ab MAbs to measure cell enlargement by forward light B7.2 Transgenic B Cells Are Not Eliminated,
scatter (FSC) and cell surface levels of class II antigen. Data were but Proliferate and Differentiate In Vivo ingated electronically for B220-positive cells from nontransgenic (thin
Presence of Antigen and T Cell Helplines) and B7.2 transgenic (dark lines) spleen cells.
The T cell±mediated elimination of B cells constitutively
expressing moderate to high levels of B7.2 was quite
surprising and may have been due to a functional abnor-Figure 5 shows the results of these adoptive transfer
experiments. In the absence of T cells, B cells occur in mality of the transgenic B cells. The proliferative re-
sponse of B7.2 transgenic B cells induced by cross-lymphoid organs in similar numbers in B7.2hi transgenic
and nontransgenic TCRb2/2 mice. Similarly, the number linking of surface IgM with anti-IgM antibody, in the
presence or absence of interleukin-4, was found to beof splenic, lymph node, and bone marrow B cells in
nontransgenic animals was not significantly different normal (data not shown). Similarly, the proliferative re-
sponse and IgM production of wild-type and B7.2whether or not they had been injected with wild-type T
cells. By contrast, in four out of five B7.2 transgenic transgenic B cells to the antigen receptor±independent
stimulus lipopolysaccharide (LPS) were not differentTCRb2/2 mice given nontransgenic syngeneic T cells,
the number of B cells in peripheral lymphoid organs was (data not shown). These results demonstrate that the
B7.2 transgenic B cellsare not defective in their capacitydecreased by z50% compared with B7.2 transgenic
TCRb2/2 mice not injected with T cells. A drastic reduc- to proliferate and differentiate into antibody-producing
cells upon stimulation with polyclonal activators in vitro.tion of B2201 cells was also apparent in the bone mar-
row. In the absence of T cells, B7.2 transgenic and non- To examine whether B7.2 transgenic B cells respond
normally to cognate interactions with Th cells, wetransgenic B cells had a similar phenotype (Figure 5B).
Interestingly, upon transfer of nontransgenic T cells, crossed the B7.2hi transgenic mice with mice carrying
HEL-specific rearranged IgH and L chain transgenesB7.2 transgenic B cells increased in size and up-regu-
lated MHC class II (Figure 5C), a phenotype similar to (Goodnow et al., 1988) and assessed the capacity of
the B cells to respond to HEL-specific TCR transgenicthat originally observed in the transgenic mice (Figure
3). In contrast, the degree of T cell activation, as as- T cells (Ho et al., 1994) when transferred together into
irradiated histocompatible recipients expressing HEL assessed by the cellular size and the expression of various
Effects of a Constitutive Expression of B7.2 on Lymphocytes
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Figure 7. The Absence of CD81 T Cells Does Not Prevent the Elimi-
nation of B7.2 Transgenic B CellsFigure 6. B7.2 Transgenic B Cells Proliferate and Differentiate into
Peripheral blood from 5-week-old nontransgenic (TG minus) andAntibody-Secreting Cells In Vivo in the Presence of Antigen and T
B7.2hi transgenic (TG plus) b2-microglobulin2/2 littermates wasCell Help
stained with anti-CD8 and anti-B220 MAbs and analyzed by flowNontransgenic (TG minus) and B7.2hi transgenic (TG plus) HEL-spe-
cytometry.cific B cells (1.5 3 106 cells) were adoptively transferred with (plus)
or without (minus) 2.5 3 106 CD41 HEL-specific T cells into irradiated
HEL-expressing recipients. The recipient mice were sacrificed 5
days after transfer. Spleen cells were enumerated, stained with anti- Golstein, 1995). Moreover, Rathmell et al. (1995) have
B220 and anti-IgMa MAbs, and analyzed by flow cytometry to deter- shown that self-reactive B cells chronically binding au-
mine the number of cells expressing the transgene-encoded IgMa toantigen do not proliferate, but instead are eliminated
(A). Spleen cells were also analyzed by spot ELISA to determine
by a Fas-dependent mechanism upon interaction withfrequencies of anti-HEL antibody±producing cells (B).
Ag-specific CD41 T cells. To determine whether the T
cell±mediated elimination of B7.2 transgenic B cells was
occurring through a Fas±Fas ligand±mediated killing,an autoantigen (Rathmell et al., 1995). As shown in Fig-
ure 6, in the absence of HEL-specific T cells, equivalent the B7.2mod transgenic mice were crossed with Fas-defi-
cient mice. As shown in Table 3, the frequency andnumbers of B7.2 transgenic and nontransgenic HEL-
specific B cells were recovered in the spleen of the absolute number of B lymphocytes in the primary and
secondary lymphoid organs were very low in the B7.2irradiated recipients, indicating that the same number
of B cells of each type established themselves after transgenic mice homozygous for the lpr mutation, indi-
cating that the T cell±mediated elimination of B cells intransfer. In the presence of HEL-specific T cells, B7.2
transgenic HEL-specific Bcells expanded and differenti- the B7.2 transgenic mice does not occur through a Fas-
dependent mechanism.ated into antibody-secreting cells as efficiently as non-
transgenic HEL-specific B cells. These results demon- It has been shown in vitro that CD28±B7 interactions
are necessary and sufficient for the proliferation andstrate that the presence of the B7.2 transgene did not
impair the B cell capacity to processand present antigen induction of CTL activity of human and murine CD81 T
cells in the absence of exogenous help (Azuma et al.,to the T cells, to provide appropriate signals to induce
T cell effector functions, and to respond to T cell help. 1992; Harding and Allison, 1993; Lanier et al., 1995;
Guerder et al., 1995). Moreover, several studies haveMoreover, these data, together with the adoptive trans-
fer experiments into B7.2 transgenic TCRb2/2 mice, indi- demonstrated that transfection of B7 molecules into
tumor cells leads to a potent anti-tumor response incate that B cells expressing high to moderate levels
of B7.2 expand and differentiate during a high affinity vivo mediated by CD81 T cells (Chen et al., 1992; Town-
send and Allison, 1993; Baskar et al., 1993; Yang et al.,antigen-specific interaction with T cells. They are elimi-
nated only when they encounter T cells that lack TCR 1995). To examine the possibility that this subset of T
cells was responsible for the elimination of the B7.2capable of high affinity recognition of antigens ex-
pressed by the B cells. Taken together, these results transgenic B cells, B7.2hi transgenic mice were crossed
to mice lacking CD81 lymphocytes owing to the disrup-suggest that CD28±B7.2 interaction provides different
signals depending on the TCR±ligand affinity. tion of the b2-microglobulin gene (Zijlstra et al., 1990).
No B cells were detected by flow cytometry in the blood
of the b2-microglobulin2/2 mice carrying the B7.2The Elimination of the B7.2 Transgenic B
Cells Is Fas Independent and Not transgene (Figure 7). These results suggest that CD81
T cells are not the primary mediators of the disappear-Mediated by CD81 T Cells
As shown in Figure 5C, upon transfer of T cells into B7.2 ance of the B7.2 transgenic B cells.
transgenic TCRb2/2 mice, B cells increased in size and
up-regulated MHC class II, suggesting that they may be Discussion
activated prior to their elimination. Fas expression was
also induced on B7.2 transgenic TCRb2/2 B cells ex- Our studiesof B7.2 transgenic mice suggest a previously
unreported function for the B7.2±CD28 system in theposed to normal T cells (data not shown). It has been
reported recently that CD41 Th1 cells induce apoptosis regulation of B cell homeostasis. In two B7.2 transgenic
lines with moderate to high levels of expression of theof activated B cells by triggering a Fas-dependent path-
way (reviewed by Krammer et al., 1994; Nagata and transgene on B cells, the numbers of peripheral and
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bone marrow B cells were significantly reduced (Tables activated by antigen receptor engagement and for which
T cell help is not available owing to the self-tolerance1 and 2). However, B cells occurred in normal numbers
in B7.2 transgenic animals lacking ab mature T cells in the T cell compartment.
The elimination of B cells expressing high levels of(Table 3; Figure 5A) or deficient in CD28 expression
(Table 3). These results indicate that the paucity of B B7.2 in the absence of T cell help closely resembles
the fate of naive HEL-binding B cells transferred intocells in the B7.2 transgenic mice is not due to a block
in B cell development, but is rather the consequence of recipients expressing soluble HEL (Cyster et al., 1994;
Cyster and Goodnow, 1995; Fulcher et al., 1996) andan elimination by an immune mechanism mediated by
the engagement of CD28 on T cells. Two observations that of mature B cells upon cross-linking of murine IgD
in vivo (Finkelman et al., 1995). In these studies, B cellsindicate that the T cell±mediated elimination of the B
cells in the B7.2mod and B7.2hi transgenic mice is not due that have received a signal via their immunoglobulin
receptor, either by antigen binding or MAbs cross-link-to the high expression of B7.2 on T cells. First, B7.2low
transgenic mice, which express functionally relevant lev- ing, disappear unless T cell help is provided. In these
situations, it is very likely that the B cells are inducedels of B7.2 only on T cells, have normal number of B
cells in the periphery and in the bone marrow (Table to express B7.2. Indeed, engagement of surface immu-
noglobulin with anti-m or anti-IgD MAbs delivers the1). Second, our adoptive transfer experiments in B7.2
transgenic TCRb2/2 mice demonstrate that B cells con- signals needed for up-regulation of B7.2 (Lenschow et
al., 1994). Moreover, it has been shown that B7.2 isstitutively expressing B7.2 are eliminated even when
exposed to nontransgenic T cells (Figure 5). The disap- rapidly up-regulated on HEL-binding B cells pulsed in
vivo with HEL or transferred into HEL-expressing recipi-pearance of B cells does not appear to be due to a
functional abnormality of the B7.2 transgenic B cells. ents (Constant et al., 1995; Cyster and Goodnow, 1995).
It is tempting to postulate that the mechanism of B cellThe transgenic B cells are not impaired in their capacity
to proliferate in vitro in response to polyclonal activators death in the absence of T cell help observed in these
studies is similar to the T cell±mediated elimination of(data not shown). Moreover, peptide-pulsed B7.2hi
transgenic B cells were able to induce in vitro the prolif- B7.2 transgenic B cells in the absence of high affinity
antigen-specific TCR engagement observed in ourstud-eration of TCR transgenic T cells specific for either MHC
class II or class I as efficiently as LPS-activated wild- ies. In both cases, the elimination of the B cells was not
affected by B cell Fas deficiency (J. C. R., C. C. G., andtype B cells, indicating that the transgene-derived B7.2
is functional (S. F., unpublished data). Most importantly, J. Cyster, unpublished data) and was accompanied by
the activation of the B cells before their disappearanceHEL-specific B7.2 transgenic B cells are not eliminated,
but rather proliferate and differentiate in the presence (Cyster and Goodnow, 1995; Fulcher et al., 1996). Fur-
thermore, it does not depend on the stage of maturationof HEL and HEL-specific T cells in vivo (Figure 6),demon-
strating that the expression of the B7.2 transgene does of the B cells (Fulcher et al., 1996). Blocking experiments
with anti-B7.2 antibody will be necessary to determinenot impair the ability of B cells to respond normally to
T cell help. whether B7.2±CD28 interaction might play a role in the
deletion of the B cells in these situations.The adoptive transfer experiments in TCRb2/2 mice
demonstrate that B cells expressing moderate to high The mechanism by which B7.2±CD28 interaction in
the absence of high affinity antigen-specific TCR en-levels of B7.2 are eliminated when exposed to T cells
that lack TCR capable of high affinity interaction with gagement results in the elimination of the B cell is not
yet clear. One attractive possibility is that B7.2 engage-self-petide±MHC complexes expressed by the B cells.
By contrast, full T±B cell collaboration between HEL- ment on the cell surface directly delivers a death signal
to the B cell. During a high affinity antigen-specific inter-specific B7.2 transgenic B cells and HEL-specific T cells
is observed in vivo in presence of HEL. From these action with T cells this signal might be antagonized by
the survival signals transduced by CD40±CD40L interac-studies, we suggest that B7.2±CD28 interaction has two
important functions in the regulation of B cell responses. tion or by cytokines secreted by the activated T cells
(or both) (Banchereau et al., 1994; Clark and Ledbetter,During high affinity TCR±ligand interaction, the T cell
receives signals from the TCR that induce the expres- 1994). B7.2 contains a cytoplasmic tail with multiple
sites for potential phosphorylation by protein kinase Csion of CD40 ligand (CD40L) (Roy et al., 1995; Jaiswal
et al., 1996). CD40L engagement of CD40 on B cells up- and therefore has the potential to be a signaling mole-
cule. Although we cannot formally exclude this possibil-regulates the expression of B7 costimulatory molecules
(reviewed by Grewal and Flavell, 1996). Under these ity, preliminary experiments indicate that the viability of
B7.2 transgenic B cells is not affected by B7.2 cross-conditions, CD28 engagement by B7 results in cytokines
release by the T cell. These cytokines, together with linking (S. F., unpublished data). It appears unlikely that
CTLA-4, which has been shown to deliver an inhibitoryCD40±CD40L interaction, promote B cell mitogenesis
(Banchereau et al., 1994; Clark and Ledbetter, 1994). signal for T cell responses (reviewed by Chambers et
al., 1996), is implicated in theT cell±mediated eliminationWhen a T cell encounters an activated B cell with high
level expression of B7.2 but presenting an antigen either of B7.2 transgenic B cells, since CTLA-4 is expressed at
very low levels if at all in the absence of TCR engagementignored by or with low affinity for the TCR, binding of
B7.2 to CD28 is not a neutral event but instead promotes (Freeman et al., 1992; Lindsten et al., 1993; Linsley et
al., 1992; Krummel and Allison, 1995; Perkins et al.,B cell death. The physiological relevance of this process
may be to limit or terminate clonal expansion of B cells 1996). Thus, despite the fact that B7.2 has a higher
affinity for CTLA-4 than for CD28 (Linsley et al., 1994),activated by T-independent antigens such as LPS of
Gram-negative bacteria or double-stranded RNA. Alter- constitutive high level expression of B7.2 on the APC
would favor CD28 engagement over CTLA-4 engage-natively, it may represent a mechanism to eliminate
newly generated self-reactive B cells that have become ment. Furthermore, if B7.2±CTLA-4 interactions were
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responsible, the elimination of B7.2 transgenic B cells and B7.2 have been detected in other studies (Lanier et
al., 1995; Levine et al., 1995). Analysis of the response ofshould also occur in CD282/2 mice, since T cells from
CD28-deficient mice are able to express functional lev- B7.2 transgenic TCRb2/2 mice injected with syngeneic T
cells and immunized with different antigens may helpels of CTLA-4 (Green et al., 1994). Therefore, it appears
that the death signal is delivered by the T cell to the B to resolve this controversial issue.
It is noteworthy that the phenotype of transgenic micecell upon CD28 engagement in the absence of apprecia-
ble TCR signaling. This notion suggests that signal two constitutively expressing B7.1 on B cells is different from
our B7.2 transgenic mice. B7.1 transgenic mice were(costimulatory signal) in the absence of signal one (TCR
signal) may not be a neutral event for the T cell. T cell impaired in their ability to make antibodies in response
to T-dependent antigens (Sethna et al., 1994). More re-responses upon CD28 engagement in the absence of
TCR occupancy are not unprecedented (Baroja et al., cently, it has been shown that spleen cells from double
transgenic mice expressing both human m chain and1988; Verwilghen et al., 1993; Brinkmann et al., 1996).
Alternatively, the death signal may be delivered upon B7.1 transferred into a nontransgenic recipient failed to
induce an antibody response or prime for a secondaryCD28±B7.2 interaction when the TCR engages self-pep-
tide±MHC complexes with partial agonist activity (Jame- antibody response following challenge with human m
chain in adjuvant (Yuschenkoff et al., 1996). In contrast,son and Bevan, 1995). Whether the elimination of B cells
constitutively expressing B7.2 is due to the occurrence we found that constitutive expression of B7.2 on B cells
had no effect on their ability to produce antibodies inof costimulation in the absence of TCR stimulation can
be assessed by examining the capacity of T cells having response to T cell help (Figure 6B). Furthermore, B7.1
transgenic mice had normal numbers of B2201 cells ina single specificity (TCR transgenic RAG2/2 T cells) to
induce the elimination of B cells when adoptively trans- their lymphoid organs (Sethna et al., 1994), indicating
that, in contrast with B7.2, constitutive expression offerred into B7.2 transgenic TCRb2/2 mice. These experi-
ments are currently in progress. B7.1 does not trigger the elimination of the B cells by
the T cells. The differences in B cell abnormalities asso-The T cell±mediated elimination of B7.2 transgenic B
cells seems to be more efficient in B7.2mod than in B7.2hi ciated with a constitutive expression of B7.1 or B7.2
may indicate that the functions of these molecules aretransgenic mice. This effect is not related to the differ-
ence in the levels of expression of B7.2 by the peripheral not completely overlapping. Indeed, it has been sug-
gested that B7.1 and B7.2 have distinct regulatory func-B cells. In both lines, the immature B cell population
(B220lowIgM2), which expressed equally high levels of tions during the development of diabetes in NOD mice
(Lenschow et al., 1995b). Some studies have also sug-the transgene (data not shown), was similarly reduced
in the bone marrow in the presence of ab mature T cells gested that B7.1 and B7.2 might have differential effects
on Th cell differentiation (Kuchroo et al., 1995; Freeman(Tables 1 and 2; Figure 5A). A reduction in the absolute
number of B cells was observed in secondary lymphoid et al., 1995). It is not yet clear how the ligation of CD28/
CTLA-4 by B7.1 or B7.2 may result in a different out-tissues of B7.2hi transgenic mice, although a consider-
able variation among mice and tissues was noted (Table come. No differences in second messengers initiated
by the two molecules have been reported to date (Ueda2). The more probable explanation for this phenomenon
is that the T cell±mediated elimination of the B cells is et al., 1995; Ghiotto-Ragueneau et al., 1996). However,
it has been shown that CD28 engagement with anti-masked by an expansion of the peripheral B cell pool
as a result of an ongoing immune response in some CD28 MAb, but not B7.1, activates p21ras (NuneÁ s et al.,
1994). Further, the CDR-3 region of CD28 and CTLA-4animals. This explanation is implied from the observa-
tion that some (but not all) B7.2hi transgenic mice carries determinants for selective recognition of B7.1
and B7.2 (Truneh et al., 1996; Kariv et al., 1996; Morton etshowed elevated levels of serum IgG1 (Figure 4B). More-
over, it is consistent with our data showing that B7.2hi al., 1996), raising thepossibility of differential signaling in
T cell by the two ligands.transgenic TCRb2/2 B cells are eliminated when ex-
posed to T cells in the absence of high affinity antigen, One aspect of the phenotype of the B7.2 transgenic
mice is particularly intriguing. We found that highly puri-but that B7.2hi transgenic HEL-specific B cells proliferate
and differentiate in the presence of HEL and HEL-spe- fied B7.2 transgenic T cells can proliferate in vitro to
limiting amounts of anti-CD3 antibody applied to plasticcific T cells. No expansion of the peripheral B cell com-
partment was apparent in B7.2mod transgenic mice, pos- wells (Figure 3), indicating that these T cells are capable
of autocrine stimulation via theCD28 pathway. However,sibly because the levels of B7.2 on B cells are insufficient
to drive T cell activation. We do not know whether the in vivo, peripheral B7.2 transgenic T cells showed only
a partial activated phenotype characterized by an up-immune responses in B7.2hi transgenic mice result from
the presentation of environmental antigens or self-anti- regulation of CD44 but not of early activation markers
such as CD69 or CD25. Despite the increased frequencygens. We did not notice a significant decline in the viabil-
ity or the health status of B7.2hi transgenic mice com- of partially activated CD41 and CD81 T cells, B7.2low
transgenic mice showed no signs of autoimmunity andpared with control mice with increasing age, arguing
against the development of autoimmune diseases in had normal levels of serum immunoglobulin isotypes
(Figure 4A). An explanation for this paradoxical findingthese animals. It is of particular interest that constitutive
high levels of B7.2 on B cells resulted in the specific might be that the regulation of T cell clonal expansion
may be altered in B7.2 transgenic mice. As already pro-increase of the Th2-induced IgG1 isotype. It has been
suggested that B7.2 may preferentially direct the devel- posed (Janeway and Bottomly, 1994; Ronchese et al.,
1994; Prabhu Das et al., 1995), T cells expressing costi-opment of Th cells along the Th2 pathway (Kuchroo et
al., 1995; Freeman et al., 1995). However, no intrinsic mulatory molecules may be able to prime anti-idiotypic
regulatory CD81 T cells, which control the expansiondifferences in lymphokine production elicited by B7.1
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FCS, followed by gentle disaggregation through a 21-gauge needle.and function of activated T cells. This mechanism would
Cells were released from spleens and lymph nodes (axillary, bra-be in force in B7.2 transgenic mice, where high levels
chial, and inguinal) by mincing the tissues and filtrating the resultingof B7.2 are found on T cells. In this regard, we observed
suspension through nylon sieves. Peripheral blood lymphocytes
an expansion of the CD81 T cell population in the spleen were prepared by centrifugation of tail vein blood (z0.3 ml into 1
of many B7.2 transgenic mice (Tables 1 and 2). Alterna- ml of Alsevier's solution) over Hystopaque, density 1.0844 (Sigma,
tively, it ispossible that abnormally high levelexpression St. Louis, MO). Cell suspensions from bone marrow and spleen were
treated with 0.165 M NH4Cl to lyse erythrocytes and washed twice.of B7.2 on T cells somehow leads to desensitization of
Cells were counted by hemocytometer, suspended to appropriatethe CD28 signal transduction pathway (Linsley et al.,
concentrations in Hank's HEPES-buffered salt solution containing1993). It is also possible that the activation signals gen-
2% FCS and 0.1% sodium azide (FACS medium) and stained with
erated by the engagement of CD28 by B7.2 expressed antibodies on ice for 25 min in the presence of 20 mg/ml of purified
on the T cells are overwhelmed by the concomitant anti-mouse CD32/CD16 to block antibody binding to murine Fc re-
engagement of CTLA-4, which transduces signals that ceptors. Cells were washed twice in FACS medium before flow
cytometric analysis on a FACScan (Becton Dickinson, Mountaindown-regulate T cell activation. Further studies will be
View, CA). Listmode data were collected with live gating on 10,000necessary to distinguish among these possibilities.
relevant cellular events and analyzed using LYSIS II software (Bec-In summary, our results clearly show that B cells ex-
ton Dickinson). Antibodies used in this study included the following:pressing moderate to high levels of B7.2 are eliminated
anti-B220-FITC or biotin (clone RA3-6B2; Caltag Laboratories, South
by T cells via a mechanism that requires CD28. This may San Francisco, CA), anti-Thy-1.2-PE (clone 5a-8; Caltag), anti-I-Ab-
be a result of a low affinity interaction of the TCR with biotin (clone KH74; Pharmingen, San Diego, CA), anti-CD62L-PE
(clone MEL-14; Pharmingen), anti-CD4-FITC or biotin (cloneself-peptides expressed by the transgenic B cells. Alter-
H129.19; Pharmingen), anti-CD8-PE or FITC (clone 53-5.8; Phar-natively, it may suggest that the B7.2±CD28 pathway,
mingen), anti-CD44-FITC or PE (clone IM7; Pharmingen), anti±abinitially shown to be necessary for the initiation of anti-
TCR-biotin (clone H57-597; Pharmingen), anti-IgMa-biotin (clonegen receptor±mediated T cell responses, transduces
DS-1;Pharmingen), anti-IgM-PE (Caltag),anti-HSA-biotin (clone M1/
signals in the absence of appreciable TCR stimulation. 69; Pharmingen), anti-CD40-PE (clone 3123; Pharmingen), anti-LFA-
Our studies of the B7.2 transgenic mice reveal that the 1-PE (clone 2D7; Pharmingen), anti-ICAM-1-FITC (clone 3E2; Phar-
B7.2±CD28 system, in addition to its critical role as a mingen), anti-CD25-FITC or biotin (clone 3C7; Pharmingen), anti-
CD69-bitotin (clone H1.2F3; Pharmingen), anti-CD45RB-FITC (clonemediator of T cell proliferation, may play a dual role
16A; Pharmingen), anti-B7-2-FITC or PE (clone GL-1; prepared inin the regulation of B cell homeostasis. When B cells
our laboratory [FITC] or Pharmingen) (PE), anti-Va11-FITC (cloneexposed a high affinity ligand for the TCR, binding of
RR8-1; Pharmingen), anti-Gr1 (clone RB6-8C5; Pharmingen), anti-
B7.2 to CD28 induces T cell±derived signals, which pro- NK1.1-biotin (clone PK136; Pharmingen), anti-CD11b-FITC (clone
motes B cell expansion and differentiation. In the ab- M1/70; Caltag), anti-Fas-FITC(clone Jo2;Pharmingen). TRI-COLOR-
sence of high affinity TCR engagement, ligation of B7.2 conjugated streptavidin (Caltag) was used to reveal biotin-coupled
antibody staining.to CD28 on the T cell results in the elimination of B cells.
This process could be important for the elimination of
irrelevant or potentialy dangerous activated B cells (or
T Cell Proliferation Assaysboth) for which T cell help is not available.
Lymph nodes cells were isolated from 6-week-old B7.2low and non-
transgenic littermates. Cell suspensions were obtained by gently
Experimental Procedures grinding tissue between frosted end of glass slides and filtrated
through nylon sieves. Cells were treated with anti±class II antibodies
Generation of B7.2 Transgenic Mice (28.16.8s and BP107) and a mixture of rabbit and guinea pig comple-
A 1.1 kb EcoRI fragment encompassing the complete open reading ment (GIBCO BRL, Gaithersberg, MA). Viable cells were isolated
frame of the murine B7.2 cDNA(provided by Dr. M. Azuma, Juntendo over Hystopaque 1.119 (Sigma) and washed extensively with com-
University School of Medicine, Tokyo, Japan) was placed under the plete RPMI 1640 medium (RPMI 1640 supplemented with 2 mM
transcriptional control of the H2-Kb promoter and immunoglobulin
L-glutamine, gentamycin, 5 3 1025 2-ME, and 10% heat-inactivated
enhancer (Pircher et al., 1989). The transgene was injected into
FCS). Residual immunoglobulin-positive cells were removed by re-
the pronucleus of fertilized eggs from (C57Bl/6J 3 CBA)F1 hybrid
petitive panning on rabbit anti±mouse IgG-coated tissue culturedonors, which were transferred to pseudopregnant CD-1 mice.
plates (100 mg/ml; Jackson ImmunoResearch, West Grove, PA).Transgenic progeny were identified by Southern blot analysis of tail
Preparations analyzed by flow cytometry were found to be .95%DNA and propagated by crossing with C57Bl/6J mice. Progeny were
Thy-1.21. Round bottom 96-well plates were coated with anti-CD3tested for the presence of the transgene by staining peripheral blood
(clone 500A2) at 0.1 mg/ml in 50 ml overnight at 48C, washed exten-lymphocytes with anti-B7.2 MAb. Mice used in the described experi-
sively with PBS, and blocked for 1 hr at 378C with complete RPMIments had been backcrossed to C57Bl/6J at least five times.
1640. T cells were added at 105 per well in 200 ml of complete RPMI
1640. Where indicated, anti-CD28 was added at 1:1000 dilution ofMice
ascites, anti-B7.2, or isotype control antibody (anti-CD16; cloneC57Bl/6J, C57Bl/6-TCRb2/2, and B6.MRL-lpr mice were purchased
2.4G2) at 20 mg/ml. Cultures were incubated at 378C for 56 hr andfrom the Jackson Laboratory (Bar Harbor,ME). CD28- and b2-micro-
then pulsed with 1 mCi of [3H]thymidine (Amersham, Arlingtonglobulin-deficient mice were provided by Dr. D. Y. Loh (Washington
Heights, IL) for an additional 16 hr before harvesting.School of Medicine, St. Louis, MO) and Dr. D. H. Raulet (University
of California at Berkeley), respectively. The derivation of mice car-
rying the MD4 anti-HEL immunoglobulin H plus L transgenes, the
Preparation and Activation of Wild-Type B CellsML5 soluble HEL transgene, and the 3A9 HEL 46-61 peptide-specific
To obtain B cells, splenic suspensions were incubated for 2 hrTCRa and b transgenes has been described previously (Goodnow
at 378C on Falcon 3025 tissue culture plates (Becton Dickinson,et al., 1988; Ho et al., 1994). Identification of mutant or wild-type Fas
Cockeysville, MD). Nonadherent cells were removed and depletedand CD28 genes in mice tail DNA was performed by PCR analysis as
of T cells by treatment with anti-CD4 (clone G. K. 1.5) and anti-CD8described (Rubio et al., 1996; Lucas et al., 1995).
(clone clone 3.155) MAbs and complement. Cells were cultured in
complete RPMI 1640 for 72 hr at 2.5 3 106 per milliliter with 25 mg/Preparation and Staining of Cell Suspensions
ml LPS (Calbiochem-Novabiochem Corp., La Jolla, CA) or with 10Single cell suspensions of femur and tibia bone marrow were pre-
pared by flushing the cavity with RPMI 1640 medium containing 2% mg/ml F(ab9)2 anti-IgM (Cappel Research Products, Durham, NC).
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